ERBB2 and neoplasm: In this study, upregulation of ERα and downregulation of HER2, pHER2 and pAKT was noted in tumours that responded to entinostat, suggesting potential off-target effects of the HDAC inhibitor through the modulation of HER2 signaling rather than reversal of acquired resistance through epigenetic silencing.